Rhumbline Advisers Grows Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Rhumbline Advisers grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 183,195 shares of the company's stock after acquiring an additional 7,225 shares during the quarter. Rhumbline Advisers owned about 0.23% of IDEXX Laboratories worth $76,933,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Hurley Capital LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at approximately $29,000. Rialto Wealth Management LLC acquired a new position in IDEXX Laboratories in the 4th quarter valued at about $30,000. Colonial Trust Co SC increased its stake in IDEXX Laboratories by 84.8% during the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after purchasing an additional 39 shares during the period. Kestra Investment Management LLC acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $38,000. Finally, Itau Unibanco Holding S.A. lifted its position in shares of IDEXX Laboratories by 540.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock worth $40,000 after purchasing an additional 81 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,046 shares of the business's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $513.74, for a total value of $537,372.04. Following the transaction, the director now directly owns 262 shares of the company's stock, valued at approximately $134,599.88. The trade was a 79.97% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.98% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on IDXX. Stifel Nicolaus upped their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research note on Monday, May 19th. Piper Sandler increased their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Morgan Stanley boosted their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Finally, Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $536.00.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded down $0.97 during trading on Wednesday, reaching $524.86. The company's stock had a trading volume of 503,327 shares, compared to its average volume of 651,941. The business's fifty day moving average price is $453.81 and its 200-day moving average price is $438.68. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $531.50. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The firm has a market cap of $42.21 billion, a price-to-earnings ratio of 49.19, a P/E/G ratio of 3.41 and a beta of 1.52.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The firm had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The business's revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the company posted $2.71 earnings per share. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.